Drug intelligence / Profile preview

BENGROW

Development stage: Unknown
Lead developer: Miotic Pharmaceuticals
Administration: Oral

Overview

**BENGROW** is an oral nutraceutical tablet marketed by Miotic Pharmaceuticals. It is a fixed-dose nutritional combination containing methylcobalamin, alpha-lipoic acid, myo-inositol, folic acid, chromium polynicotinate, selenium dioxide monohydrate, benfotiamine, and sulbutiamine. The formulation is intended to provide vitamin and antioxidant nutritional support, including support for vitamin B12-dependent neurologic and metabolic functions. Miotic Pharmaceuticals lists BENGROW as a 10-tablet product. ([mioticpharma.com](https://mioticpharma.com/main-division.html))

Brand names: BENGROW
Other names: Methylcobalamin + vitamins

Targets

MTHFR (Methylenetetrahydrofolate reductase)CBS (Cystathionine beta-synthase)MTR (Methionine synthase)

Beyond the preview

Go deeper on BENGROW.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BENGROW.

Explore the full profile